Last-Hope drug offered to advanced colon cancer patients

NCT ID NCT06195514

NO_LONGER_AVAILABLE Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

Summary

This program provided compassionate early access to the drug fruquintinib for adults with advanced colorectal cancer that had stopped responding to all standard treatments. Participants took oral capsules in repeating cycles. The goal was to control the cancer and extend life when no other satisfactory options were available.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

Explore the condition pages connected to this study.